Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Product information and disease descriptionProduct descriptionProduct information

Dosage forms and strengths

3 evidence topics · 3 sources

Phase 3 doses and injection volumes
ArmQuoted dose and volume
Onvuzosiran every 6 months“ADX-324 300 mg Q6M (1.5ml)”
Onvuzosiran every 3 months“ADX-324 240 mg Q3M (1.2ml)”
Placebo matched to the 6-month regimen“Placebo (1.5 ml) n=15”
Placebo matched to the 3-month regimen“Placebo (1.2 ml) n=15”
Material safety data sheet

No evidence found.